Astec Lifesciences receives ratings action from ICRA

Astec Lifesciences announced that ICRA has reaffirmed/ assigned the long-term rating of [ICRA]AA- (pronounced 'ICRA double A minus') and the short term rating of [ICRA]A1+ (pronounced 'ICRA A one plus') for the Rs. 839 crore (enhanced from Rs.574 crore) Fund Based and Non-Fund Based facilities of the Company. Further, ICRA has revised the outlook on the long-term rating from 'Stable' to 'Positive'
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
More From This Section
Buzzing :
Greece in crisisTravel & Budget & EuropeSaaS $ Email MarketingHarnautBlacklisting Policy 2Question Paper Leak 2A big moment for small armsAI in Financial Markets: How Technology is Changing Investing'India's size and diversity make it a powerful innovation engine'Datanomics: Housing, gold loans drive household debt to a decade highSamrat ChoudharyEl Nino
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Jun 25 2022 | 10:43 AM IST

